ORIGINAL ARTICLE

RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis

John Hilkens,¹ Nikki C Timmer,¹ Mandy Boer,¹ Gerjon J Ikin,¹ Matthias Schewe,² Andrea Sacchetti,² Martijn A J Koppens,¹ Ji-Ying Song,³ Elvira R M Bakker¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2016-311606>).

¹Department of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands

²Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Centre, Rotterdam, The Netherlands

³Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Correspondence to

Dr Elvira R M Bakker, or Dr J Hilkens, Department of Molecular Genetics, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; e.bakker@nki.nl j.hilkens@nki.nl

Received 5 February 2016

Revised 30 June 2016

Accepted 5 July 2016

Published Online First

9 August 2016

ABSTRACT

Objective The gross majority of colorectal cancer cases results from aberrant Wnt/β-catenin signalling through adenomatous polyposis coli (*APC*) or *CTNNB1* mutations. However, a subset of human colon tumours harbour, mutually exclusive with *APC* and *CTNNB1* mutations, gene fusions in *RSPO2* or *RSPO3*, leading to enhanced expression of these R-spondin genes. This suggested that *RSPO* activation can substitute for the most common mutations as an alternative driver for intestinal cancer. Involvement of *RSPO3* in tumour growth was recently shown in *RSPO3*-fusion-positive xenograft models. The current study determines the extent into which solely a gain in *RSPO3* actually functions as a driver of intestinal cancer in a direct, causal fashion, and addresses the in vivo activities of *RSPO3* in parallel.

Design We generated a conditional *Rspo3* transgenic mouse model in which the *Rspo3* transgene is expressed upon Cre activity. Cre is provided by cross-breeding with *Lgr5*-GFP-Cre^{ERT2} mice.

Results Upon in vivo *Rspo3* expression, mice rapidly developed extensive hyperplastic, adenomatous and adenocarcinomatous lesions throughout the intestine. *RSPO3* induced the expansion of *Lgr5*⁺ stem cells, Paneth cells, non-Paneth cell label-retaining cells and *Lgr4*⁺ cells, thus promoting both intestinal stem cell and niche compartments. Wnt/β-catenin signalling was modestly increased upon *Rspo3* expression and mutant *Kras* synergised with *Rspo3* in hyperplastic growth.

Conclusions We provide in vivo evidence that *RSPO3* stimulates the crypt stem cell and niche compartments and drives rapid intestinal tumorigenesis. This establishes *RSPO3* as a potent driver of intestinal cancer and proposes *RSPO3* as a candidate target for therapy in patients with colorectal cancer harbouring *RSPO3* fusions.

INTRODUCTION

Although in the majority of colorectal cancer cases the Wnt/β-catenin pathway is deregulated through mutations in adenomatous polyposis coli (*APC*) or β-catenin (*CTNNB1*), two studies reported gene fusions of the R-spondin family members *RSPO2* and *RSPO3* in a subset of human colon tumours, accompanied by enhanced expression of these genes.^{1 2} R-spondins are secreted proteins that potentiate Wnt/β-catenin signalling following binding of the leucine-rich repeat-containing G-protein coupled receptors (LGR), in the intestine represented by LGR5 and LGR4. Whereas LGR5 predominantly

Significance of this study

What is already known on this subject?

- Overactivation of Wnt/β-catenin signalling through *APC* or *CTNNB1* mutation underlies the majority of colorectal cancer cases.
- A subset of human colon tumours harbour gene fusions of *RSPO2* or *RSPO3*, associated with enhanced expression of these genes.
- R-spondin proteins promote Wnt/β-catenin signalling.
- Inhibition of *RSPO3* reduces the growth of existing *RSPO3*-fusion-positive tumours in xenograft models.

What are the new findings?

- *Rspo3* expression causes rapid development of adenoma and adenocarcinoma in the intestine, establishing *RSPO3* as an efficient, causal driver of intestinal cancer. *RSPO3* drives extensive crypt hyperplasia and expands multiple crypt components, including *Lgr5*⁺ stem cells, Paneth cells, non-Paneth cell label-retaining cells and *Lgr4*⁺ cells.
- The robust *RSPO3*-induced phenotype is associated with a modest increase in Wnt/β-catenin signalling.

How might it impact on clinical practice in the foreseeable future?

- The potency of *RSPO3* to stimulate the crypt stem cells and niche cells, and to actively drive tumorigenesis, proposes *RSPO3* as a useful candidate target for therapy in patients with colorectal cancer harbouring *RSPO3* fusions.

marks the cycling stem cells at the crypt bottom that fuel the continuous renewal of the intestinal epithelium, LGR4 is present throughout the entire crypt, on cycling stem cells, transient amplifying cells and Paneth cells.^{3 4} Paneth cells fulfil a crucial role in the intestinal crypts by providing the stem cells with a supporting niche.⁵ In addition to the cycling stem cells, a pool of more quiescent +4 stem cells has been identified that coexpress *Lgr5* and Paneth cell markers.^{6–8} These label-retaining cells (LRCs) serve as Paneth cell precursors and as ‘reserve’ stem cells, able to acquire cycling capacities upon damage.^{7 8}

RSPO2 and *RSPO3* fusions are mutually exclusive with *APC* and *CTNNB1* mutations in human colon

► <http://dx.doi.org/10.1136/gutjnl-2016-312584>

CrossMark

To cite: Hilkens J, Timmer NC, Boer M, et al. *Gut* 2017;**66**:1095–1105.

tumours, suggesting that a gain in RSPO can substitute for these most common mutations as an alternative driver of intestinal tumorigenesis.¹ Moreover, all the RSPO-fusion-positive colon tumours were described to harbour a mutation in either *KRAS* or *BRAF*, mutations that often co-occur in *APC* mutant settings as well.¹ Involvement of RSPO3 in growth of pre-existing tumours was recently shown in RSPO3-fusion-positive xenograft models, where anti-RSPO3 treatment inhibited tumour growth.^{9–10} Whether indeed solely a gain in RSPO3 has the potency to act as a causal driver of intestinal cancer remained to be determined. Here, we demonstrate that RSPO3 is an oncogenic driver, rapidly causing intestinal cancer and extensive crypt hyperplasia, concomitantly stimulating stem cells and supportive niche cells.

RESULTS

Rspo3 expression induces extensive intestinal hyperplasia and tumorigenesis

To investigate the *in vivo* consequence of a gain in RSPO3, we generated a conditional *Rspo3* transgenic mouse model. The used *Rspo3* transgene was verified to encode secreted and biologically active RSPO3 protein using β -catenin luciferase reporter assays (see online supplementary figure S1A). In generating the mouse model, the *Rspo3* coding sequence was inserted in the inverse orientation, flanked by two pairs of oppositely oriented, homologous *Lox* sites and behind the ubiquitous CAGGS promoter (figure 1 and see online supplementary figure S1B). This design enables conditional *Rspo3* expression upon Cre activity. Cre was provided by crossing our *Rspo3^{inv}/+* (*Rspo3^{inv}*) mice to *Lgr5*-GFP-Cre^{ERT2} (*Lgr5*) mice¹¹ and activation of the inducible Cre^{ERT2} recombinase was achieved by tamoxifen injection at the age of 2 months, unless mentioned otherwise. Single transgenic *Lgr5* and *Rspo3^{inv}* animals served as controls and were treated identically as double transgenic *Lgr5*;*Rspo3* mice. Efficient expression of sense-oriented transgenic *Rspo3* upon tamoxifen injection was confirmed in double transgenic *Lgr5*;*Rspo3* animals exclusively and throughout the small and large intestine (see online supplementary figure S1D). Correspondingly, we confirmed RSPO3 protein expression, observed in double transgenic mice only (see online supplementary figure S1E).

Transgenic *Rspo3* expression caused abdominal enlargement and often led to rectum prolapses in double transgenic animals within several weeks, urging their analysis mostly within 2 months following induction. The intestines of *Lgr5*;*Rspo3* mice appeared elongated and distended, and microscopic analysis revealed mucosal thickening caused by extensive epithelial hyperplasia (figure 2A, B). This robust phenotype was observed exclusively though in all double transgenic animals. Hyperplastic lesions extended upwards from crypts to the lumen, integrating with pre-existing villi and appearing as multiple microadenomatous nodules, typically showing dislocated Paneth cells and high rates of mitosis and local necrotic changes (figure 2B, C). These lesions were observed throughout the entire small intestine, in the caecum and proximal colon (see online supplementary figure S2A). In addition, the majority of animals developed adenomas (figure 2D), some of which even progressed to adenocarcinomas as indicated by local invasion (figure 2E). On average 2.5 (± 2.3) tumours, mostly adenomas, were detected per *Lgr5*;*Rspo3* mouse, most of which developed in the jejunum, ileum and caecum (figure 2F, G). When tamoxifen was injected at 25 days of age, the phenotype and tumour incidence (average 2.6 $\pm$ 2.4, see online supplementary figure S2B) were comparable to that of mice injected at 2 months of age.

These data provide evidence that *Rspo3* drives rapid intestinal tumorigenesis and extensive hyperplastic growth.

RSPO3 expands *Lgr5*⁺ stem cells and Paneth cells

We examined the occurrence of crypt cells by staining for green fluorescent protein (GFP) representing *Lgr5*-GFP-Cre^{ERT2} expressing cells and lysozyme indicating Paneth cells. In *Lgr5* control mice, we observed GFP expression specifically in the crypt bottom stem cells and in a stochastic fashion, as has been reported (figure 3A upper panel).¹¹ In the intestines of *Lgr5*;*Rspo3* animals, we noticed an expansion of the *Lgr5*-GFP⁺ stem cell zone in hyperplastic and neoplastic lesions (figure 3A). In parallel, we observed a clear increase in the abundance of Paneth cells in the *Rspo3*-induced lesions in *Lgr5*;*Rspo3* mice (figure 3B). Paneth cells were dislocated, presenting higher upwards towards the lumen, reaching higher up than the *Lgr5*⁺ cells. More specifically in adenoma, Paneth cells were observed dispersed throughout the entire tumour, whereas *Lgr5*-positive cells were present mainly in the lower parts of these lesions. Notably, Paneth cells were prominently present at the invading front of adenocarcinomatous lesions, as were *Lgr5*⁺ cells though less consistent. Even in the proximal large intestine, RSPO3 induced the appearance of lysozyme-positive Paneth cells, which are normally absent in the mouse large intestine (figure 3C). In accordance with the abnormal growth and crypt expansion observed in *Rspo3* expressing mice, proliferation was clearly enhanced, as well as the amount of Sox9-positive cells (figure 4A, B). Nuclear β -catenin was detected in some Paneth cells though appeared hardly affected by transgenic *Rspo3* expression (figure 4C), suggesting a relatively moderate gain in Wnt/ β -catenin signalling in our *Lgr5*;*Rspo3* model compared with *Apc* mutant mouse models. Indeed, we did detect clear nuclear β -catenin in tumours of age-matched and background-matched *Apc*^{Min} mice (see online supplementary figure S3A). Taken together, RSPO3 imposes hyperplastic, adenomatous and adenocarcinomatous growth in the mouse intestine, accompanied by expansion of the crypt compartment, including *Lgr5*⁺ stem cells, Paneth cells and proliferative progenitor cells.

RSPO3 causes expansion of additional crypt cell types

In the setting of *Apc* deletion in *Lgr5* cells, *Lgr5*⁺ stem cells have been reported as the cells of origin in the developing adenoma.^{12–13} We performed lineage tracing experiments to examine a possible *Lgr5*⁺ stem cell derivation of the *Rspo3*-induced lesions. *Lgr5*;*Rspo3* mice were cross-bred to mTmG Cre reporter mice, enabling detection of an intense GFP signal in the progeny upon Cre-mediated switching, well distinguishable from the weaker GFP staining derived from the *Lgr5*-GFP-Cre^{ERT2} cassette. In *Lgr5*;mTmG mice without transgenic *Rspo3*, ribbons of GFP^{hi} staining presented from the crypts upwards into the villi (figure 5A). However, upon *Rspo3* expression the overall occurrence of GFP^{hi} cells seemed reduced, appearing less frequent and only in small foci, leaving the vast majority of the *Rspo3*-induced hyperplasias and tumours untraced (figure 5A). A similar reduction in lineage tracing was observed upon *Rspo3* expression using Rosa26-LacZ mice as a Cre reporter (figure 5B). Although stochastic expression and suboptimal efficiency of Cre could cause underrepresentation of *Lgr5*-derived lineage tracing, this holds true both for mice expressing as well as lacking transgenic *Rspo3*, and thus cannot explain the relative reduction in *Lgr5*-Cre-driven lineage tracing in *Rspo3* expressing mice. This indicates that *Lgr5*⁺ cells are not the sole cells of origin and

Figure 1 Simplified schematic representation of the *Rspo3*^{inv} mouse model. The *Rspo3* coding sequence is inserted in the inverse orientation between two pairs of oppositely oriented *Lox* sites and behind the CAGGS promoter. Cre activity causes inversion of the *Rspo3* transgene into the sense orientation using either one of the homologous *LoxP* or *Lox511* pairs, leading to the middle two transgenic *Rspo3* products. Subsequent excision of the remaining sequences in between the homologous *Lox* sites that are now in the same direction provides a product with sense oriented, irreversible *Rspo3* expression. Both intermediate and locked *Rspo3* recombination products encode *Rspo3* sense mRNA.

alternative cell types must be involved in the development of the *Rspo3*-driven lesions.

Given that RSPO3 is a secreted protein, most likely it will act not only in an autocrine but also in a paracrine fashion on adjacent cells expressing the LGR5 and LGR4 receptor. *Lgr4* has been reported to be expressed throughout the entire crypt compartment, present on crypt base columnar cells, Paneth cells and transient amplifying cells.⁴ *Lgr4* in situ hybridisation revealed that *Lgr4*⁺ cells presented abundantly throughout the entire *Rspo3*-induced lesions, demonstrating the efficient expansion of these cells upon *Rspo3* expression (figure 5C). This abundance of *Lgr4*⁺ cells is in contrast to the more sparsely present *Lgr5*⁺ cells, which were restricted to the lesion bases (figures 3B and 5C). Importantly, a comparable distribution pattern of LGR4⁺ and LGR5⁺ cells was observed in xenografts of RSPO3-fusion-positive human colon tumours. In these patient-derived tumours, LGR5 expression was limited and focal, whereas LGR4 was expressed abundantly throughout the entire tumours, confirming the expansion of LGR4⁺ cells in the human situation (figure 5D).

In addition to the cycling stem cells, more quiescent stem cells were recently identified that coexpress *Lgr5* and Paneth cell markers. In contrast to the crypt bottom stem cells, these cells are label-retaining, a feature that also holds true for Paneth cells. Moreover, these quiescent cells which are located at the +4 position serve as Paneth cell precursors and as 'reserve' stem cells, acquiring cycling stem cell capacities under specific circumstances.^{7,8} To investigate the influence of RSPO3 on these quiescent cells, we performed repetitive bromodeoxyuridine (BrDU) injections, and allowed label retention for 1 week or 2 weeks, which was the maximum we could achieve given the *Rspo3*-induced morbidity. Subsequently, double staining was performed for BrDU and lysozyme, allowing discrimination between non-Paneth and Paneth cell LRCs. Transgenic *Rspo3* expression clearly enhanced the presence of total LRCs, 1 week and 2 weeks following BrDU injections (see online supplementary figure S3B and figure 5E, F respectively). Moreover, among these LRCs, lysozyme-negative LRCs were especially enhanced upon *Rspo3* expression, indicating a relative increase in non-Paneth cell LRCs, or, the presumptive Paneth cell precursors that may acquire stem cell activities.

Together these data indicate that *Rspo3* induces lesions that are only partially derived from *Lgr5*⁺ cells, though in parallel

causes an abundant expansion of *Lgr4*⁺ cells, label-retaining Paneth cells and their presumptive quiescent precursors.

RSPO3 imposes a crypt-associated gene expression profile

RNAseq analysis was performed on jejunum tissue of *Lgr5* and *Rspo3*^{inv} single transgenic control mice and *Lgr5*;*Rspo3* double transgenic animals (n=8 per genotype). Unsupervised clustering on gene expression profiles showed tight clustering of *Lgr5*; *Rspo3* tissues (see online supplementary figure S4). *Lgr5* and *Rspo3*^{inv} single transgenic controls clustered together, indicating their similarity and justifying to pool them as controls. We found 587 differentially expressed genes of which 255 were increased and 332 decreased (figure 6A, filtered p<0.05 and fold change >1.5). Gene ontology analysis revealed that most significantly enriched molecular and cellular functions upon *Rspo3* expression were related to cellular growth, proliferation, movement and signalling (figure 6B). Wnt/β-catenin signalling appeared as the second most significantly upregulated signalling pathway, while an increased expression of phospholipase genes *Pla2g5*, *Pla2g2a*, *Pla2g2f*, *Pla2g4c* and *Pla2g12a* underlied high ranking of the majority of the other pathways, except for the axonal guidance pathway (figure 6B and see online supplementary figure S5A). Taking a closer look at individual genes involved in cellular proliferation, growth and Wnt/β-catenin signalling in the intestine, we found a broad panel of genes among the upregulated genes. In addition to 12 upregulated Wnt signalling related genes, we observed increased transcripts of crypt stem cell markers *Ascl2*, *Hopx*, *Cdca7*, *Tnfrsf19* and *Msi1* and of Paneth cell associated genes *Lyz1* and *Pla2g2a* (figure 6C). Also, enhanced *Lgr4* expression was observed, corresponding to the above described expansion of *Lgr4*⁺ cells. Conversely, differentiation markers of non-crypt cell lineages were downregulated, among which *Sis* and *Muc2*, and most significantly downregulated functions involve metabolism and associated signalling pathways (see online supplementary figure S5B–D). These expression data match our findings of abnormal cellular growth and crypt hyperplasia, including expansion of *Lgr4*⁺, Paneth and stem cells and also indicate significantly increased Wnt/β-catenin signalling.

To assess whether the increased mRNA levels of crypt-associated genes solely reflects the expansion of crypt cells or also concerns differential gene expression at the cellular level, *Lgr5*-GFP stem cells and Paneth cells were sorted by flow

Figure 3 Rspo3 induces expansion of Lgr5 stem cells and Paneth cells. Immunohistochemical staining of (A) GFP and (B) lysozyme in representative hyperplastic and neoplastic lesions in the small intestine. (C) Lysozyme staining showing Paneth cell metaplasia in hyperplastic proximal colon (middle panel) and in adenoma at the caecum-colon transition (lower panel).

Rspo3 spheres did not maintain this cystic phenotype over time but rather showed crypt budding and differentiation after several days. The crypt regions developing in Lgr5;Rspo3 organoids showed aberrant morphology, with the lumen appearing open and being relatively large (figure 7A, B and see online supplementary figure S6). Furthermore, whereas control organoids rapidly died following depletion of exogenous RSPO1 from the medium, Lgr5;Rspo3 organoids survived and maintained their typical morphological phenotype as observed in the presence of RSPO1 (figure 7C), indicating the functional

replacement of exogenous RSPO1 by the transgenic RSPO3. Robust proliferation capacity of the Lgr5;Rspo3 organoids in the absence of exogenous RSPO1 was confirmed by Ki67 staining (figure 7D).

Mutant *Kras* enhances RSPO3-induced hyperplastic, though not neoplastic growth

All human colon tumours with *RSPO2* or *RSPO3* fusion transcripts harboured a mutation in either *KRAS* or *BRAF*¹. To investigate the relevance of mutant *Kras* in the setting of enhanced

Figure 4 *Rspo3*-induced lesions are highly proliferative. Immunohistochemical staining of (A) Ki67, (B) Sox9 and (C) β -catenin in representative *Rspo3*-induced lesions. Inserts show predominant membranous β -catenin expression besides mild nuclear detection in Paneth cells.

RSPO3, we cross-bred our *Lgr5*;*Rspo3* mice with *Kras*^{G12V} mice. F1 hybrid progeny was injected with tamoxifen at 25 days of age, activating Cre and enabling expression of *Rspo3* and of the mutant *Kras* allele. Triple transgenic mice expressing both *Rspo3* and mutant *Kras* (*Lgr5*;*Rspo3*;*Kras* genotype) appeared more morbid than corresponding *Lgr5*;*Rspo3* controls, although survival did not differ significantly between *Lgr5*;*Rspo3*;*Kras* and *Lgr5*;*Rspo3* cohorts (see online supplementary figure S7). *Lgr5*;*Kras* mice displayed no signs of morbidity and accordingly, microscopic analysis of the intestines revealed no phenotypical alterations (figure 8A). However, mutant *Kras* activation in combination with transgenic *Rspo3* expression revealed an increase in the severity of the hyperplastic phenotype (figure 8A), indicating that mutant *Kras* and RSPO3 synergistically stimulate hyperplastic growth. In contrast, tumour numbers were not significantly different between the *Lgr5*;*Rspo3* and *Lgr5*;*Rspo3*;*Kras* cohorts (figure 8B). Restricted to the *Lgr5*;*Rspo3*;*Kras* cohort, three cases of adenomatosis were observed, in which animals displayed multiple adenomatous lesions throughout the small intestine, merging

into one another and hampering exact quantification. Given the reported synergy between mutant *Kras* and mutant *Apc* on Wnt/ β -catenin signalling,¹⁴ we performed immunohistochemical β -catenin stainings on the intestines of mice expressing transgenic *Rspo3* with and without mutant *Kras* (figure 8C). Nuclear translocation of β -catenin was hardly observed both in *Lgr5*;*Rspo3* and *Lgr5*;*Rspo3*;*Kras* intestines. Accordingly, qPCR analyses showed that RSPO3 increased the expression of *Axin2*, *Cd44*, *Sox9* and *Rnf43*, but coexpression of the mutant *Kras* allele from the *Lgr5*-GFP-Cre^{ERT2} cells did not raise the expression levels any further (figure 8D). Together these data indicate that in this mouse model, when expressed in *Lgr5*⁺ cells, mutant *Kras* synergises with RSPO3 in hyperplastic growth, but not in promoting Wnt signalling or tumorigenesis.

DISCUSSION

Recognising the prominent role of *APC* and *CTNNB1* mutations in human colorectal cancer, many mouse studies have investigated the effects of activating the associated Wnt/ β -catenin signalling pathway, showing proliferative and tumorigenic

Figure 5 *Rspo3* expands additional crypt cell types. (A) GFP immunostaining in the small intestine of *Lgr5;mTmG* mice with or without transgenic *Rspo3*. GFP^{high} cells indicate mTmG reporter activity, distinguishable from GFP^{mid} cells derived from the *Lgr5*-GFP-Cre^{ERT2} cassette. (B) X-gal staining of *Lgr5;R26-LacZ* mice with or without transgenic *Rspo3*. In situ hybridisation showing *Lgr4* and *Lgr5* mRNA expression (C) in an *Rspo3*-induced adenoma of an *Lgr5;Rspo3* mouse and (D) in a xenograft of a human *RSPO3*-fusion-positive colon tumour. (E) Representative example of bromodeoxyuridine (BrDU)-lysozyme double immunostaining in *Lgr5* single and *Lgr5;Rspo3* double transgenic jejunum, 2 weeks after repetitive BrDU injections. Arrows indicate lysozyme-positive label-retaining cells (LRCs) (black) and lysozyme-negative LRCs (grey). (F) Quantification of BrDU-retaining cells in the jejunum, being either lysozyme-negative or lysozyme-positive (2 weeks after BrDU), showing averages and SDs over three independent experiments. *p<0.05, **p<0.01, Student's *t*-test.

phenotypes.^{12 15–21} Gene fusions leading to enhanced *RSPO3* expression have been proposed as a possible alternative to these most common *APC* or *CTNNB1* mutation routes in driving intestinal cancer.¹ We show that transgenic *Rspo3* expression induces a proliferative phenotype resembling that of other Wnt activating mouse models. Moreover, we provide in vivo evidence that *RSPO3* stimulates stem cell and niche compartments and drives rapid intestinal tumorigenesis. In line with reported Wnt/ β -catenin promoting activities of R-spondin, transgenic *Rspo3* expression potentiated the Wnt signalling pathway, as was apparent from multiple gene expression analyses and cystic organoid morphology. We demonstrated that *RSPO3* enhanced

Wnt/ β -catenin signalling both in *Lgr5*⁺ stem cells and Paneth cells. Despite this, we hardly observed nuclear translocation of β -catenin in *RSPO3*-induced lesions, indicating that the gain in Wnt signalling is relatively low, especially compared with *Apc* mutant mouse models. In this regard, it might be interesting to investigate the involvement of alternative signalling factors, and the collective increase of five phospholipase genes propose these as interesting candidates. Among those, *Pla2g2a* has recently been described as an important regulatory stem cell niche factor.²²

Thus, while *RSPO3* raises Wnt/ β -catenin signalling to a relatively modest level, it drives tumorigenesis efficiently.

Figure 7 RSPO3 alters organoid morphology and allows RSPO1-independent growth. (A) Organoids grown from control and Lgr5;Rspo3 transgenic mice, 2 (upper) and 5 (lower) days after seeding, showing the increase in spheroid growth, aberrant crypt formation and open lumen upon *Rspo3* expression. (B) Percentage of spheres of total organoids in culture, bars indicate the averages with SDs from minimally three experiments. * $p < 0.05$, ** $p < 0.01$, Student's t-test. (C) Organoids from control mice disintegrate following the depletion of exogenous RSPO1, whereas Lgr5;Rspo3 organoids survive and show similar phenotype as with exogenous RSPO1. (D) Ki67 staining visualising proliferation absence and presence in control versus Lgr5;Rspo3 organoids, respectively, in the absence of exogenous RSPO1.

more differentiated intestinal cell types have been shown to act as tumour initiating cells under specific circumstances.^{8 19 23}

Taken together, we demonstrate that RSPO3 stimulates Lgr5⁺ stem cells, Lgr4⁺ cells, Paneth cells and their presumptive quiescent precursors by causing their expansion as well as promoting the expression of related genes, including Wnt/ β -catenin signalling genes. Considering that R-spondins are secreted proteins, this implies that RSPO3 may potentially influence a broad spectrum of stem cell and niche cell types in patients with colorectal cancer harbouring RSPO3 fusions. Unfortunately, not much knowledge exists to date about the occurrence and functioning of alternative stem cells, Paneth cells and their precursors in the human colon, besides that part of human colon tumours harbour Paneth cells, and their presence in adenoma is associated with an increased risk for developing additional colonic adenomas.^{16 24 25} We provide in vivo evidence that RSPO3 stimulates the intestinal stem cell and niche compartments and drives rapid tumorigenesis, proposing RSPO3 as a promising candidate therapy target for patients with colorectal cancer carrying RSPO3 fusions.

MATERIALS AND METHODS

Generation of *Rspo3*^{inv} transgenic mouse model

A detailed description of the generation of the *Rspo3* cassette that allows conditional expression of *Rspo3* after Cre activation, and the generation of the FVB.129P2-Gt(Rosa)26Sor⁶ (CAG-Rspo3)^{Nki}/A (MGI:5697338, abbreviated to *Rspo3*^{inv}) transgenic founder strain is provided in the online supplementary information. Shortly, the *Rspo3* coding sequence was inserted in antisense orientation between two sets of non-homologous *Lox* sites in a head to head orientation, 3' to the CAGGS promoter in a *Rosa26* gene targeting cassette.²⁶ The obtained *Rspo3*^{inv}

construct (figure 1 and see online supplementary figure S1A) was introduced into strain 129 derived IB10 E14ES cells by electroporation and selected embryonic stem (ES) cells were injected into 129/Ola blastocysts. Founder strains were back-crossed for five times to 129/Ola, followed by more than nine generations back-crossing to FVB.

Mouse strains and treatments

All mouse strains were maintained heterozygous. The *Rspo3*^{inv} mice were provided with inducible Cre by cross-breeding with *Lgr5*-GFP-Cre^{ERT2} transgenic mice¹¹ on FVB background. Cre was activated by intraperitoneal tamoxifen injection (200 μ L 10 mg/mL in corn oil) of single and double transgenic progeny at the age of 2 months, followed by analysis 1–2 months later, unless mentioned otherwise. BrDU was administered by intraperitoneally injecting 100 μ L (10 mg/mL in phosphate-buffered saline (PBS)), six times on two consecutive days, and 2 weeks after tamoxifen. Double transgenic *Lgr5*-GFP-Cre^{ERT2}; *Rspo3*^{inv} mice were cross-bred to mTmG mice (back-crossed to FVB),²⁷ Rosa26-LacZ mice,²⁸ and *Kras*^{LSL G12V} mice.²⁹ Progeny was injected with tamoxifen at day 25, followed by analysis within 1–2 months.

Histology and immunohistochemistry

Intestines were formalin-fixed and paraffin-embedded (FFPE), followed by H&E staining according to routine protocols. Cultured organoids were fixed in 4% PFA and embedded in low-melting agarose prior to paraffin embedding. Immunohistochemistry was performed on consecutive sections using antigen retrievals, antibodies and visualisation as indicated in online supplementary table SI. For quantification of BrDU/lysozyme-positive cells, Aperio

Figure 8 Mutant *Kras* and *Rspo3* synergise in hyperplastic though not neoplastic growth. (A) H&E stainings of small intestine of Lgr5;Kras, Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice, showing augmentation of the hyperplastic phenotype in triple transgenic mice. The right-most panel shows a representative example of adenomatosis as observed in Lgr5;Rspo3;Kras mice exclusively. (B) Number of adenoma (left panel) and adenocarcinoma (right panel) observed in Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice, lines indicating the median. Open triangles represent cases of adenomatosis, where tumour numbers are an estimation of ≥ 20 . (C) β -catenin immunostaining on representative neoplastic lesions in small intestine of Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice. Inserts show that nuclear β -catenin detection is not affected by mutant *Kras*. (D) Relative expression of Wnt target genes in the jejunum ($n=8$ per genotype). ** $p<0.01$, *** $p<0.001$, Student's t-test.

ImageScope software was used to precisely discriminate single or double staining for each cell. Twenty-five GFP-positive jejunum crypts were counted per mouse, followed by averaging the three experiments. X-gal staining was performed as described in the online supplementary information.

RNA in situ hybridisation

RNA in situ hybridisation was performed using RNAscope 2.0 high definition (HD) Brown for FFPE (Advanced Cell Diagnostics (ACD)) and following manufacturer's instructions with minor adjustments. Pretreatment (1) 10 min RT, pretreatment (2) boil 15 min and pretreatment (3) 10 min in 40°C hybridisation oven. Probes Mm Lgr4 318321, Mm Lgr5 312171, Hs LGR4 460551 and Hs LGR5 311021 (ACD) were

hybridised 2 hours at 40°C. Sections of xenograft tumours derived from *RSPO3*-fusion-positive human colon tumours were obtained from Crown BioScience.

RNA isolation, cDNA synthesis and expression analysis of whole tissue

For the purpose of RNA sequencing analysis, RNA was isolated from jejunum tissues using TRIzol reagent (Ambion Life Technologies) followed by purification using the MinElute Cleanup Kit (Qiagen). Illumina TruSeq mRNA libraries were generated using the TruSeq RNA Library Preparation Kit v2 (Illumina) and samples were sequenced 51 bp single-end using the Illumina HiSeq2000 platforms (Illumina). Everything was performed according to routine manufacturer's protocols.

Limma's Voom was used for normalisation and expression data were analysed using Ingenuity Pathway Analysis.

For RT-PCR and qPCR purposes, RNA was isolated from jejunum tissues using TissueLyser LT (Qiagen) and RNeasy Plus Mini Kit (Qiagen), followed by cDNA generation using Maxima First Strand cDNA Synthesis Kit (Fisher Scientific). RT-PCR was performed using MyTaq Red DNA Polymerase and qPCR using SensiFAST SYBR Hi-ROX Kit (both GCBiotech). Primers are shown in online supplementary table SII. Expression levels were normalised using *Actb*.

Crypt isolation, culture and cell preparation for flow cytometric sorting

Small intestinal crypts were isolated and cultured as described,^{6, 30} using mice that received Tamoxifen at the age of 25 days. Cultured organoids were dissociated with narrowed Pasteurs' pipettes, seeded into Matrigel (Corning) and maintained for indicated durations, without or with exogenous RSPO1. RSPO1 was supplemented as 10% conditioned medium, derived from HEK293T cells transfected with an *Rspo1* expression vector.³¹

For flow cytometric sorting, isolated crypts were incubated with TrypLE (Life Technologies) and 2000 U/mL Dnase (Sigma) 10 min, 37°C. Dissociated cells were passed through a 40 µm strainer and stained 30 min at 4°C with BV421-conjugated-TER119, BV421-conjugated-CD31, BV421-conjugated-CD45 and APC-conjugated CD24 (all BioLegend). Sorting was performed using FACS AriaIII (BD Bioscience) as described previously.⁶ In short, single viable epithelial cells (DAPI⁺ and lineage⁻) were selected based on CD24, GFP and side scatter (SSC). Paneth cells (CD24^{hi}SSC^{hi}) and Lgr5-GFP^{hi} stem cells were sorted in three independent runs.

Expression analysis of sorted cells

RNA was isolated following the Trizol reagent protocol (Invitrogen), adding 1 µL Glyco-blue (15 mg/mL Ambion). RNA was converted into cDNA using the high capacity RNA-to-cDNA kit (Applied Biosystems) and employed in a preamplification step using the TaqmanPreAmp Master Mix (Applied Biosystems). Quantitative PCR was performed using TaqMan probes and assays (Applied Biosystems). Everything was performed according to manufacturer's instructions. Expression levels were corrected for *Actb* expression.

Acknowledgements The authors thank the Netherlands Cancer Institute's animal facility, animal pathology department (E Riem, J van Ooij, L de Vrije and J van der Meer) and microarray facility (I de Rink) for their service and technical assistance, and Professor Dr H te Riele for providing FFPE materials of *Apc*^{Min} mice. The authors also thank A Vendel-Zwaagstra for performing the TOP/FOP β-catenin reporter assay and Professor Dr R Fodde for thoughtful discussion and supporting collaborative experiments.

Contributors ERMB and JH: conceived, designed and oversaw the project and wrote the manuscript. Mouse studies: ERMB, NCT, JH and MB. Histology: J-YS, ERMB, NCT and JH. Gene expression analysis: ERMB, MB, GJI, MS. Flow cytometric sorting: AS. Organoid studies: ERMB and MAJK.

Competing interests None declared.

Ethics approval All animal experiments were performed with approval of the Animals Ethics Committee and according to Dutch legislation.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Seshagiri S, Stawiski EW, Durinck S, *et al.* Recurrent R-spondin fusions in colon cancer. *Nature* 2012;488:660–4.
- Shimura K, Kahyo T, Kato H, *et al.* RSPO fusion transcripts in colorectal cancer in Japanese population. *Mol Biol Rep* 2014;41:5375–84.
- de Lau W, Barker N, Low TY, *et al.* Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. *Nature* 2011;476:293–7.
- Mustata RC, Van Loy T, Lefort A, *et al.* Lgr4 is required for Paneth cell differentiation and maintenance of intestinal stem cells ex vivo. *EMBO Rep* 2011;12:558–64.
- Sato T, van Es JH, Snippert HJ, *et al.* Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. *Nature* 2011;469:415–18.
- Roth S, Franken P, Sacchetti A, *et al.* Paneth cells in intestinal homeostasis and tissue injury. *PLoS ONE* 2012;7:e38965.
- Clevers H. Stem cells: a unifying theory for the crypt. *Nature* 2013;495:53–4.
- Buczacki SJ, Zecchini HI, Nicholson AM, *et al.* Intestinal label-retaining cells are secretory precursors expressing Lgr5. *Nature* 2013;495:65–9.
- Storm EE, Durinck S, de Sousa e Melo F, *et al.* Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. *Nature* 2016;529:97–100.
- Chartier C, Raval J, Axelrod F, *et al.* Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types. *Cancer Res* 2016;76:713–23.
- Barker N, van Es JH, Kuipers J, *et al.* Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007;449:1003–7.
- Barker N, Ridgway RA, van Es JH, *et al.* Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 2009;457:608–11.
- Schepers AG, Snippert HJ, Stange DE, *et al.* Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. *Science* 2012;337:730–5.
- Janssen KP, Alberici P, Fsihi H, *et al.* APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. *Gastroenterology* 2006;131:1096–109.
- Andreu P, Colnot S, Godard C, *et al.* Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. *Development* 2005;132:1443–51.
- Andreu P, Peignon G, Slomianky C, *et al.* A genetic study of the role of the Wnt/β-catenin signalling in Paneth cell differentiation. *Dev Biol* 2008;324:288–96.
- Asfaha S, Hayakawa Y, Muley A, *et al.* Krt19(+)/Lgr5(-) Cells Are Radioresistant Cancer-Initiating Stem Cells in the Colon and Intestine. *Cell stem cell* 2015;16:627–38.
- Harada N, Tamai Y, Ishikawa T, *et al.* Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. *EMBO J* 1999;18:5931–42.
- Huels DJ, Sansom OJ. Stem vs non-stem cell origin of colorectal cancer. *Br J Cancer* 2015;113:1–5.
- Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. *Nat Genet* 2008;40:915–20.
- Sansom OJ, Reed KR, Hayes AJ, *et al.* Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. *Genes Dev* 2004;18:1385–90.
- Schewe M, Franken PF, Sacchetti A, *et al.* Secreted phospholipases A2 are intestinal stem cell niche factors with distinct roles in homeostasis, inflammation, and cancer. *Cell Stem Cell* 2016;19:38–51.
- Schwitalla S, Fingerle AA, Cammareri P, *et al.* Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. *Cell* 2013;152:25–38.
- Joo M, Shahsafaei A, Odze RD. Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/β-catenin/Tcf pathway. *Hum Pathol* 2009;40:872–80.
- Pai RK, Rybicki LA, Goldblum JR, *et al.* Paneth cells in colonic adenomas: association with male sex and adenoma burden. *Am J Surg Pathol* 2013;37:98–103.
- Vooijs M, Jonkers J, Berns A. A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. *EMBO Rep* 2001;2:292–7.
- Muzumdar MD, Tasic B, Miyamichi K, *et al.* A global double-fluorescent Cre reporter mouse. *Genesis* 2007;45:593–605.
- Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet* 1999;21:70–1.
- Guerra C, Mijimolle N, Dhawahir A, *et al.* Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. *Cancer cell* 2003;4:111–20.
- Sato T, Vries RG, Snippert HJ, *et al.* Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature* 2009;459:262–5.
- Koppens MA, Bounova G, Gargiulo G, *et al.* Deletion of polycomb repressive complex 2 from mouse intestine causes loss of stem cells. *Gastroenterology*. Published Online First: 21 Jun 2016. doi: 10.1053/j.gastro.2016.06.020.